Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab.
Lassau N, Coiffier B, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Benatsou B, Bonastre J, Koscielny S.
Lassau N, et al. Among authors: luciani a.
Ann Oncol. 2016 Oct;27(10):1922-8. doi: 10.1093/annonc/mdw280. Epub 2016 Aug 8.
Ann Oncol. 2016.
PMID: 27502701
Free PMC article.